Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing and delivering drugs for people living with rare metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.
| Revenue (TTM) | $634.21M |
| Gross Profit (TTM) | $561.28M |
| EBITDA | $41.95M |
| Operating Margin | 8.61% |
| Return on Equity | -11.60% |
| Return on Assets | 2.49% |
| Revenue/Share (TTM) | $2.06 |
| Book Value | $0.88 |
| Price-to-Book | 16.59 |
| Price-to-Sales (TTM) | 7.17 |
| EV/Revenue | 7.41 |
| EV/EBITDA | 87.32 |
| Quarterly Earnings Growth (YoY) | -95.50% |
| Quarterly Revenue Growth (YoY) | 23.70% |
| Shares Outstanding | $314.00M |
| Float | $311.44M |
| % Insiders | 0.69% |
| % Institutions | 104.39% |
Volatility is currently contracting
Bitcoin jumped 4.6% to $72,475.25 – a roughly 12% gain over the past two days after the digital asset was trading near $63,000 earlier this week.
BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition of Amicus Therapeutics adds GALAFOLD and POMBILITI + OPFOLDA, boosting 2026 revenue guidance to $3.825–$3.925 billion and targeting 20% YoY growth. VOXZOGO expansion into hypochondroplasia and ongoing clinical trials represent major catalysts, with topline Phase 3 data expected in Q2 2026.
BioMarin (BMRN) has declined over 12% since January 2025, despite prior optimism. The investment thesis centers on the potential of VOXZOGO and Amicus's two approved therapies to drive future upside. Current share weakness may present a buying opportunity given VOXZOGO's prospects.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FOLD and any ticker you trade — then tracks every position and per-strategy win rate.
